THE DRUG DOCKET

FDA clears first generic of the Climara Pro menopause hormone patch

Announced 20 October, Zydus's once-weekly estradiol-and-levonorgestrel transdermal system is the first generic of Climara Pro, a combined oestrogen-progestogen patch for menopausal symptoms and bone loss.

The Food and Drug Administration announced on 20 October the approval of the first generic version of Climara Pro, a once-weekly skin patch that delivers two hormones at once for the treatment of menopausal symptoms [s1]. The product, made by Zydus Pharmaceuticals (USA) Inc., is an estradiol and levonorgestrel transdermal system delivering 0.045 mg per day of estradiol and 0.015 mg of levonorgestrel [s1].

What is new here is not the medicine but the competition. Climara Pro, a registered trademark of Bayer, has been available as a brand-name product; this is the first time the FDA has cleared a generic of it [s1]. A generic contains the same active ingredients at the same strength and is expected to work the same way, which is what opens the door to lower-cost alternatives once a brand's exclusivity lapses.

What the patch is for

The system is approved for two uses in women who still have a uterus: the treatment of moderate to severe vasomotor symptoms — the hot flushes and night sweats of menopause — and the prevention of postmenopausal osteoporosis, the bone-thinning that raises fracture risk after menopause [s1].

The detail that a reader should not skip is why it combines two hormones rather than one. Many patches deliver oestrogen alone. This one pairs estradiol, an oestrogen, with levonorgestrel, a progestogen [s1]. Oestrogen given on its own can thicken the lining of the uterus and raise the risk of endometrial hyperplasia, a precancerous overgrowth; adding a progestogen counters that effect [s1]. That is precisely why the combined patch is indicated only for women with an intact uterus — a woman who has had a hysterectomy has no such lining to protect, and the progestogen component would carry risk without that benefit [s1].

Once a week, through the skin

The practical appeal is dosing. The patch is applied once a week and absorbed through the skin, which the FDA frames as an alternative to taking a hormone pill every day [s1]. Transdermal delivery also bypasses the first pass through the liver that oral hormones undergo, a difference that matters to clinicians weighing options, though the approval notice does not make comparative safety claims on that basis.

The risks are the risks of hormone therapy

A generic inherits the safety profile of the product it copies, and menopausal hormone therapy carries a well-established set of cautions that this approval does nothing to soften. The label's contraindications — the situations in which the patch should not be used — include undiagnosed abnormal genital bleeding; a current or past history of breast cancer; other oestrogen-dependent cancers; active or prior deep-vein thrombosis or pulmonary embolism; active or prior arterial clotting disease such as stroke or heart attack; liver impairment or disease; known clotting disorders including protein C, protein S or antithrombin deficiency; and hypersensitivity to either hormone [s1].

The most common adverse reactions reported in at least 5% of users were application-site reactions, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome [s1].

Why it matters

Hormone therapy remains the most effective treatment for the vasomotor symptoms of menopause, and access to it is shaped partly by cost. A first generic is an access story more than a clinical one: it does not change what the medicine does, but it adds a competitor to a brand-name market, which over time tends to lower prices. For patients and prescribers, the arrival of a generic is a reason to revisit options, not a change in the underlying evidence about who benefits from hormone therapy and who should avoid it.

What to watch

The open questions are commercial and practical: when the generic reaches pharmacies, how its price compares with the brand, and whether supply is steady. None of that is settled by an approval notice. The clinical calculus — weighing symptom relief and bone protection against the clotting and cancer cautions above — is unchanged, and remains a decision for a woman and her clinician.

This article describes a regulatory approval and is not medical advice. Decisions about menopausal hormone therapy, including whether it is appropriate at all, are for patients and their treating clinicians.

Sources

  1. FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women — U.S. Food and Drug Administration , October 20, 2026

More on

Related coverage